These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 17656262

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
    Radojkovic M, Ristic S, Pavlovic S, Colovic M.
    Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
    Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M.
    Cancer Genet Cytogenet; 2005 Oct 01; 162(1):57-62. PubMed ID: 16157201
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
    Yamamoto M, Kakihana K, Kurosu T, Murakami N, Miura O.
    Cancer Genet Cytogenet; 2005 Mar 01; 157(2):104-8. PubMed ID: 15721630
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
    Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C.
    Blood Cells Mol Dis; 2006 Mar 01; 37(2):111-5. PubMed ID: 16908206
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X, Saw KM, Eaves A, Eaves C.
    J Natl Cancer Inst; 2007 May 02; 99(9):680-93. PubMed ID: 17470736
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
    Martin SE, Sausen M, Joseph A, Kingham BF.
    Cancer Genet Cytogenet; 2010 Sep 02; 201(2):133-4. PubMed ID: 20682399
    [No Abstract] [Full Text] [Related]

  • 38. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.
    Aziz Z, Iqbal J, Akram M, Saeed S.
    Cancer; 2007 Mar 15; 109(6):1138-45. PubMed ID: 17315159
    [Abstract] [Full Text] [Related]

  • 39. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
    Metzke-Heidemann S, Harder L, Gesk S, Schoch R, Jenisch S, Grote W, Siebert R, Schlegelberger B.
    Genes Chromosomes Cancer; 2001 May 15; 31(1):10-4. PubMed ID: 11284030
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.